135 related articles for article (PubMed ID: 11957148)
1. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
3. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
Di Lieto A; De Falco M; Mansueto G; De Rosa G; Pollio F; Staibano S
Steroids; 2005 Feb; 70(2):95-102. PubMed ID: 15631865
[TBL] [Abstract][Full Text] [Related]
4. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
6. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
7. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
8. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas.
Di Lieto A; De Falco M; Staibano S; Iannotti F; Scaramellino M; Salvatore G; Mansueto G; Granata P; Pontillo M; Pollio F; De Rosa G
Int J Gynecol Pathol; 2003 Oct; 22(4):353-8. PubMed ID: 14501815
[TBL] [Abstract][Full Text] [Related]
9. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
10. The combined effect of a GnRH analog in premenopause plus postmenopausal estrogen deficiency for the treatment of uterine leiomyomas in perimenopausal women.
de Aloysio D; Altieri P; Pretolani G; Romeo A; Paltrinieri F
Gynecol Obstet Invest; 1995; 39(2):115-9. PubMed ID: 7737580
[TBL] [Abstract][Full Text] [Related]
11. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
12. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
13. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
14. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
15. Fas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Huang SC; Tang MJ; Hsu KF; Cheng YM; Chou CY
J Clin Endocrinol Metab; 2002 Oct; 87(10):4580-6. PubMed ID: 12364438
[TBL] [Abstract][Full Text] [Related]
16. The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography.
Aleem FA; Predanic M
Gynecol Endocrinol; 1995 Sep; 9(3):253-8. PubMed ID: 8540296
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
[TBL] [Abstract][Full Text] [Related]
19. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
Hansen LM; Batzer FR; Corson SL; Bello S
J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
